Related Experiment Video
Updated: Jul 16, 2026
05:29
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
HMGB1 as a potential therapeutic target
Haichao Wang1, Wei Li, Richard Goldstein
1Department of Emergency Medicine, North Shore University Hospital, New York University School of Medicine, USA.
Novartis Foundation Symposium
|March 27, 2007
Summary
High mobility group box 1 (HMGB1) is a key mediator in lethal sepsis, released late in the disease process. Inhibiting HMGB1 offers a promising therapeutic strategy with a wide treatment window for sepsis.
Area of Science:
- Biomedical Science
- Immunology
- Critical Care Medicine
Background:
- Sepsis is a leading cause of death in intensive care units, driven by dysregulated inflammatory responses.
- High mobility group box 1 (HMGB1) is implicated as a significant mediator in sepsis pathogenesis.
Purpose of the Study:
- To investigate the role of HMGB1 as a late mediator in lethal endotoxemia and sepsis.
- To evaluate the therapeutic potential of targeting HMGB1 in experimental sepsis models.
Main Methods:
- Assessed circulating HMGB1 levels in endotoxemic and septic animal models.
- Administered recombinant HMGB1 to mice to observe sepsis-like clinical signs.
- Tested the efficacy of anti-HMGB1 antibodies and various inhibitors in protecting against lethal sepsis.
Main Results:
- Elevated HMGB1 levels were observed in a delayed manner in septic animals.
- Recombinant HMGB1 administration induced sepsis-like symptoms, including organ failure.
- Anti-HMGB1 treatments and inhibitors demonstrated protective effects, even when administered late in sepsis.
Conclusions:
- HMGB1 acts as a crucial late mediator in lethal endotoxemia and sepsis.
- Targeting HMGB1 presents a viable therapeutic approach for sepsis with a broad therapeutic window.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...